About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT01423110

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis

Lead sponsor: Novartis Pharmaceuticals•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Age

40 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•\- Males and Females aged 40-80 with a confirmed diagnosis of sporadic Inclusion Body Myositis

Exclusion Criteria

•Unable to walk at least 3 meters without assistance from another person
•Use of oral beta agonists, oral corticosteroids, androgens or androgen inhibitors, or intravenous gamma globulin in the last 6 months
•patients with a history or presence of renal impairment and/or liver disease

Related studies

RECRUITINGEARLY Phase 1

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

NCT06479863 · Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies

COMPLETEDPhase 1

Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis

NCT04421677 · Inclusion Body Myositis, Sporadic Inclusion Body Myositis

COMPLETEDPhase 3

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

NCT02573467 · Sporadic Inclusion Body Myositis

Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study

NCT02735447 · Sporadic Inclusion Body Myositis

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 17, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment14

Start dateAug 2011

Last updatedDec 17, 2020

Condition

Sporadic Inclusion Body Myositis

Locations shown

Novartis Investigative Site

Scottsdale, Arizona

Novartis Investigative Site

Kansas City, Kansas

Novartis Investigative Site

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 17, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions